US Patent Issued to Anavex Life Sciences on April 29 for "A2-73 as a therapeutic for insomnia, anxiety and agitation" (New York Inventor)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,285,403, issued on April 29, was assigned to Anavex Life Sciences Corp. (New York).

"A2-73 as a therapeutic for insomnia, anxiety and agitation" was invented by Christopher U. Missling (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg."

The patent was filed on Oct. 9, 2023, under Application No. 18/483,128.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/...